NDAINTRAVENOUSINJECTABLE
Approved
Jul 2001
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
6
Data completeness
4/8 — Partial
DEFINITY (perflutren) by Lantheus Medical Imaging is ultrasound contrast activity [moa]. First approved in 2001.
Drug data last refreshed 5h ago · AI intelligence enriched Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DEFINITY (perflutren) is an intravenous ultrasound contrast agent that enhances echocardiographic imaging by increasing blood pool echogenicity. It consists of perflutren microspheres that reflect ultrasound waves, enabling improved visualization of cardiac structures and function. The drug is used adjunctively in echocardiography to opacify the left ventricular cavity and improve endocardial border definition.
Peak10.6 years to LOE
DEFINITY remains in peak commercial stage with established market presence and stable demand driven by routine echocardiography procedures across hospital and imaging centers.
Mechanism of Action
Ultrasound Contrast Activity
Pharmacologic Class:
Contrast Agent for Ultrasound Imaging
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (6)
An Ascending Dose Comparison of MVT-100 to Definity in Healthy Volunteers
Started Apr 2019
16 enrolled
Heart Diseases
DEF-315 Better Accuracy in Ejection Fraction (EF) Assessment With DEFINITY
Started Dec 2018
160 enrolled
Cardiac Disease
DEF-314 Better Accuracy in Ejection Fraction (EF) Assessment With DEFINITY
Started Oct 2018
153 enrolled
Cardiac Disease
A Study of Commercial DEFINITY® to Monitor the Effects of the Heart's Pulmonary Artery Pressure
Started Jul 2009
32 enrolled
Pulmonary Heart Disease
Retrospective Safety Study to Compare Mortality in Intensive Care Unite (ICU) Patients Undergoing Echocardiography With or Without DEFINITY®
Started Jun 2008
4,300,000 enrolled
Cardiovascular Disease
Worked on DEFINITY at Lantheus Medical Imaging? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.